These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28339312)

  • 1. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
    Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
    Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma.
    Yin X; Xiao Y; Han L; Zhang B; Wang T; Su Z; Zhang N
    AAPS PharmSciTech; 2018 Jul; 19(5):2133-2143. PubMed ID: 29714002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
    Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
    J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
    Yang S; Zhang B; Gong X; Wang T; Liu Y; Zhang N
    Int J Nanomedicine; 2016; 11():2329-43. PubMed ID: 27307733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
    Xiao Y; Liu Y; Yang S; Zhang B; Wang T; Jiang D; Zhang J; Yu D; Zhang N
    Colloids Surf B Biointerfaces; 2016 May; 141():83-92. PubMed ID: 26844644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
    Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
    Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
    Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
    Thapa RK; Choi JY; Poudel BK; Hiep TT; Pathak S; Gupta B; Choi HG; Yong CS; Kim JO
    ACS Appl Mater Interfaces; 2015 Sep; 7(36):20360-8. PubMed ID: 26315487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
    Park W; Chen J; Cho S; Park SJ; Larson AC; Na K; Kim DH
    ACS Appl Mater Interfaces; 2016 May; 8(20):12711-9. PubMed ID: 27159350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
    Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
    Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
    Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
    Cao H; Wang Y; He X; Zhang Z; Yin Q; Chen Y; Yu H; Huang Y; Chen L; Xu M; Gu W; Li Y
    Mol Pharm; 2015 Mar; 12(3):922-31. PubMed ID: 25622075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
    Sun W; Wang Y; Cai M; Lin L; Chen X; Cao Z; Zhu K; Shuai X
    Biomater Sci; 2017 Nov; 5(12):2468-2479. PubMed ID: 29106433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
    Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
    Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy.
    Wang T; Zhang J; Hou T; Yin X; Zhang N
    Nanoscale; 2019 Aug; 11(29):13934-13946. PubMed ID: 31305839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
    Malarvizhi GL; Retnakumari AP; Nair S; Koyakutty M
    Nanomedicine; 2014 Nov; 10(8):1649-59. PubMed ID: 24905399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
    Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
    Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
    Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
    Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.